Guihua Zhuang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guihua Zhuang has a total of 425 co-authors. Here are the top co-authors by number of shared publications:
- Lei Zhang
Northwestern Polytechnical University, Xi'an, China
21 shared publications - Mingwang Shen
China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi’an Jiaotong University Health Science Center
14 shared publications Rui Li
Heidelberg Institute of Global Health (HIGH), Faculty of Medicine and University Hospital Heidelberg University Heidelberg Germany
14 shared publicationsZhuoru Zou
Department of Epidemiology and Biostatistics School of Public Health, Xi'an Jiaotong University Health Science Center Xi'an China
14 shared publicationsRuyi Xia
School of Public Health Xi'an Medical University Xi'an China
13 shared publicationsPeng Li
Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR China
12 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1774108
Risk factors of long COVID among discharged patients with omicron infection in Changzhi, China: a retrospective cohort study
Background: Relatively little is known about long COVID (LC) in China, particularly regarding the effects of recent Omicron sub-lineages. Therefore, we systematically assessed the prevalence and risk factors for developing LC. Methods: This retrospective cohort study included COVID-19 patients who had been hospitalized at two hospitals in Changzhi, China, between December 15, 2022 and April 30, 2024. All patients were interviewed via telephone ≥ 3 months after discharge. The follow-up study was conducted between July 18 and August 20, 2024. Logistic regression models were used to analyze risk factors for developing long COVID. Results: A total of 2,765 patients (1,407 male [50.9%]; median [IQR] age 70.0 [59.0–78.0] years) were successfully evaluated by telephone; 458 (16.6%) self-reported long COVID symptoms. The most common symptom was fatigue (4.9%), followed by muscle weakness (3.9%), sleep difficulties (3.0%), brain fog (2.8%) and cough (2.5%). Severe COVID-19 patients had a higher risk of LC than non-severe patients (OR = 1.275, 95% CI: 1.036–1.570). In subgroup analyses stratified by follow-up time, overweight patients (OR = 1.564; 95% CI: 1.052–2.326), patients with ≥ 7 acute-phase symptoms (OR = 1.275; 95% CI: 1.064–1.528), and farmer (OR = 1.439, 95% CI: 1.047, 1.976) had a higher risk of LC, whereas individuals who received immunosuppressant therapy had a lower risk (OR = 0.691, 95% CI: 0.504, 0.948). In addition, aged ≥ 50 years (OR = 2.441, 95% CI: 1.175–5.072) and underweight status (OR = 2.183; 95% CI: 1.115–4.273) were associated with a higher risk of muscle weakness. Conclusion: This study provides valuable insights into LC after discharge, with 16.6% of discharged patients reporting symptoms. It is essential to monitor at-risk individuals according to identified risk factors for public health efforts.
- 12 August 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1774108
Open AccessRisk factors of long COVID among discharged patients with omicron infection in Changzhi, China: a retrospective cohort study
Background: Relatively little is known about long COVID (LC) in China, particularly regarding the effects of recent Omicron sub-lineages. Therefore, we systematically assessed the prevalence and risk factors for developing LC. Methods: This retrospective cohort study included COVID-19 patients who had been hospitalized at two hospitals in Changzhi, China, between December 15, 2022 and April 30, 2024. All patients were interviewed via telephone ≥ 3 months after discharge. The follow-up study was conducted between July 18 and August 20, 2024. Logistic regression models were used to analyze risk factors for developing long COVID. Results: A total of 2,765 patients (1,407 male [50.9%]; median [IQR] age 70.0 [59.0–78.0] years) were successfully evaluated by telephone; 458 (16.6%) self-reported long COVID symptoms. The most common symptom was fatigue (4.9%), followed by muscle weakness (3.9%), sleep difficulties (3.0%), brain fog (2.8%) and cough (2.5%). Severe COVID-19 patients had a higher risk of LC than non-severe patients (OR = 1.275, 95% CI: 1.036–1.570). In subgroup analyses stratified by follow-up time, overweight patients (OR = 1.564; 95% CI: 1.052–2.326), patients with ≥ 7 acute-phase symptoms (OR = 1.275; 95% CI: 1.064–1.528), and farmer (OR = 1.439, 95% CI: 1.047, 1.976) had a higher risk of LC, whereas individuals who received immunosuppressant therapy had a lower risk (OR = 0.691, 95% CI: 0.504, 0.948). In addition, aged ≥ 50 years (OR = 2.441, 95% CI: 1.175–5.072) and underweight status (OR = 2.183; 95% CI: 1.115–4.273) were associated with a higher risk of muscle weakness. Conclusion: This study provides valuable insights into LC after discharge, with 16.6% of discharged patients reporting symptoms. It is essential to monitor at-risk individuals according to identified risk factors for public health efforts.
- Open Access
- 28 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1867430
Longitudinal trajectories of long COVID among hospitalized patients with omicron infection in Changzhi, China
Background: Understanding the persistence of long COVID (LC) among discharged patients with Omicron infection remains limited. Methods: The study used a retrospective longitudinal cohort to evaluate the dynamic trajectory of LC after hospital discharge and to identify factors associated with new-onset and persistent LC following Omicron infection. Patients admitted to Heping Hospital Affiliated to Changzhi Medical College and Changzhi People’s Hospital for coronavirus disease 2019 between 15 December 2022 and 30 April 2024 were included. The first follow-up was conducted from 18 July to 20 August 2024, and the second from 9 May 2025 to 13 June 2025. Results: Of the 3,777 discharged patients, 1,922 [median (IQR) age, 70.0 (59.0–78.0) years; 968 male individuals (50.4%)] who completed both follow-up visits were included in the final analysis. The median (IQR) time from discharge to the second follow-up was 727 (688–854) days. At the second follow-up, 292 patients (15.2%) were diagnosed with LC, including 121 (6.3%) with persistent LC and 171 (8.9%) with new-onset LC. The most common symptoms were muscle weakness, sleep difficulties, fatigue, cough, and dyspnea at rest. Notably, the proportions of muscle weakness, sleep difficulties, cough, arthralgia, and palpitations increased significantly, whereas brain fog decreased significantly from 2.8% at the first follow-up to 0.4% at the second follow-up. Overall, antiviral treatment (OR = 1.503; 95% CI: 1.063–2.126), female sex (OR = 3.729; 95% CI: 1.145–12.147), being a farmer as an occupation (OR = 4.695; 95% CI: 2.188–10.101), and BMI < 18.5 kg/m 2 (OR = 5.291; 95% CI: 1.115–25.000) were associated with increased new-onset LC susceptibility, whereas having one or more complications was associated with decreased new-onset LC susceptibility (OR = 0.329; 95% CI: 0.125–0.865). Conclusion: Omicron-infected patients report a persistent burden of symptoms consistent with the WHO definition of LC after discharge. These findings provide valuable information on the dynamic trajectory of long-term health outcomes in patients infected with Omicron. However, the non-specific nature of the symptoms should be considered when interpreting these findings.
- 28 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1867430
Open AccessLongitudinal trajectories of long COVID among hospitalized patients with omicron infection in Changzhi, China
Background: Understanding the persistence of long COVID (LC) among discharged patients with Omicron infection remains limited. Methods: The study used a retrospective longitudinal cohort to evaluate the dynamic trajectory of LC after hospital discharge and to identify factors associated with new-onset and persistent LC following Omicron infection. Patients admitted to Heping Hospital Affiliated to Changzhi Medical College and Changzhi People’s Hospital for coronavirus disease 2019 between 15 December 2022 and 30 April 2024 were included. The first follow-up was conducted from 18 July to 20 August 2024, and the second from 9 May 2025 to 13 June 2025. Results: Of the 3,777 discharged patients, 1,922 [median (IQR) age, 70.0 (59.0–78.0) years; 968 male individuals (50.4%)] who completed both follow-up visits were included in the final analysis. The median (IQR) time from discharge to the second follow-up was 727 (688–854) days. At the second follow-up, 292 patients (15.2%) were diagnosed with LC, including 121 (6.3%) with persistent LC and 171 (8.9%) with new-onset LC. The most common symptoms were muscle weakness, sleep difficulties, fatigue, cough, and dyspnea at rest. Notably, the proportions of muscle weakness, sleep difficulties, cough, arthralgia, and palpitations increased significantly, whereas brain fog decreased significantly from 2.8% at the first follow-up to 0.4% at the second follow-up. Overall, antiviral treatment (OR = 1.503; 95% CI: 1.063–2.126), female sex (OR = 3.729; 95% CI: 1.145–12.147), being a farmer as an occupation (OR = 4.695; 95% CI: 2.188–10.101), and BMI < 18.5 kg/m 2 (OR = 5.291; 95% CI: 1.115–25.000) were associated with increased new-onset LC susceptibility, whereas having one or more complications was associated with decreased new-onset LC susceptibility (OR = 0.329; 95% CI: 0.125–0.865). Conclusion: Omicron-infected patients report a persistent burden of symptoms consistent with the WHO definition of LC after discharge. These findings provide valuable information on the dynamic trajectory of long-term health outcomes in patients infected with Omicron. However, the non-specific nature of the symptoms should be considered when interpreting these findings.
- Open Access
- 20 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
The effects of meteorological factors on hemorrhagic fever with renal syndrome in Yichun, China: a major Apodemus-type endemic city
Historically, Yichun City has borne the highest burden of Hemorrhagic Fever with Renal Syndrome (HFRS) in China, with incidence exhibiting marked fluctuations between 2005 and 2023. Despite this, HFRS-weather associations in Yichun remain poorly characterized. We analyzed weekly time-series data on HFRS cases and meteorological factors (mainly temperature, humidity, and precipitation) from 2005 to 2023 using random forest models to identify optimal lags, distributed lag non-linear models, and generalized additive models. We identified a symmetric unimodal relationship for temperature (peak risk at 13.66 °C; RR = 1.77, 95% CI: 0.92-3.39), a right-skewed pattern for relative humidity, and a distinct inverse J-shaped pattern for precipitation. Lag-response analysis indicated that the strongest associations occurred at 26 weeks for temperature, 12 weeks for relative humidity, and 16 weeks for precipitation. Temperature showed complex delayed responses with both protective and risk-increasing phases (~ 4-6 months), while precipitation and humidity primarily exhibited protective effects. Formal interaction testing revealed no statistically significant two-way or three-way interactions among meteorological variables (all P > 0.05), indicating that each factor operates independently rather than synergistically. These findings offer actionable evidence for designing targeted, climate-informed HFRS prevention strategies in Yichun and similar high-burden regions.
- 20 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessThe effects of meteorological factors on hemorrhagic fever with renal syndrome in Yichun, China: a major Apodemus-type endemic city
Historically, Yichun City has borne the highest burden of Hemorrhagic Fever with Renal Syndrome (HFRS) in China, with incidence exhibiting marked fluctuations between 2005 and 2023. Despite this, HFRS-weather associations in Yichun remain poorly characterized. We analyzed weekly time-series data on HFRS cases and meteorological factors (mainly temperature, humidity, and precipitation) from 2005 to 2023 using random forest models to identify optimal lags, distributed lag non-linear models, and generalized additive models. We identified a symmetric unimodal relationship for temperature (peak risk at 13.66 °C; RR = 1.77, 95% CI: 0.92-3.39), a right-skewed pattern for relative humidity, and a distinct inverse J-shaped pattern for precipitation. Lag-response analysis indicated that the strongest associations occurred at 26 weeks for temperature, 12 weeks for relative humidity, and 16 weeks for precipitation. Temperature showed complex delayed responses with both protective and risk-increasing phases (~ 4-6 months), while precipitation and humidity primarily exhibited protective effects. Formal interaction testing revealed no statistically significant two-way or three-way interactions among meteorological variables (all P > 0.05), indicating that each factor operates independently rather than synergistically. These findings offer actionable evidence for designing targeted, climate-informed HFRS prevention strategies in Yichun and similar high-burden regions.
- Open Access
- 12 June 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Integrating inflammation, insulin resistance, and visceral adiposity: the C-reactive protein–triglyceride–glucose-Chinese visceral adiposity (CTI–CVAI) index is associated with cardiovascular disease risk across CKM stages 0–3 in a nationwide prospective cohort
Early-stage (0-3) cardiovascular-kidney-metabolic (CKM) syndrome populations require urgent cardiovascular disease (CVD) prevention. Chronic inflammation, insulin resistance, and visceral adiposity are three core interactive CVD pathogenic pathways, while current biomarkers fail to integrate all three. This study aimed to explore the association of the novel three-dimensional composite index CTI-CVAI with incident CVD and its predictive value in Chinese adults with CKM stages 0-3. This nationwide prospective cohort study used data from the China Health and Retirement Longitudinal Study (CHARLS, 2011-2020), including 6728 participants aged ≥ 45 years with CKM stages 0-3. CTI-CVAI was calculated by combining the C-reactive protein-triglyceride-glucose index (CTI) and Chinese visceral adiposity index (CVAI). Cox regression, restricted cubic spline, survival analysis, ROC curves, and reclassification analysis were used to evaluate its value. Subgroup and multiple sensitivity analyses, including competing-risks models, were conducted to assess the robustness of the results. During a median follow-up of 9 years, the overall CVD incidence was 23.83%. CTI-CVAI elevation showed a linear, dose-dependent correlation with increased CVD risk (P < 0.001). After full confounder adjustment, per 1-SD CTI-CVAI increment increased CVD risk by 32% (HR = 1.32, 95% CI 1.26-1.39, P < 0.001), and the highest quartile exhibited 2.07-fold higher risk than the lowest (HR = 2.07, 95% CI 1.77-2.42, P < 0.001). Restricted cubic spline analysis revealed a linear association between CTI-CVAI and incident CVD (P for non-linearity > 0.05). CTI-CVAI demonstrated improved risk reclassification (NRI = 0.0566, P < 0.001) compared with single biomarkers. The association was stable across most subgroups. All sensitivity analyses yielded reliable, robust results. CTI-CVAI is independently and linearly associated with incident CVD risk in Chinese adults with CKM stage 0-3. As a low-cost, accessible biomarker integrating three key pathological pathways, it optimizes early CVD risk stratification and reclassification, providing a promising tool for targeted CVD prevention in CKM high-risk populations.
- 12 June 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Open AccessIntegrating inflammation, insulin resistance, and visceral adiposity: the C-reactive protein–triglyceride–glucose-Chinese visceral adiposity (CTI–CVAI) index is associated with cardiovascular disease risk across CKM stages 0–3 in a nationwide prospective cohort
Early-stage (0-3) cardiovascular-kidney-metabolic (CKM) syndrome populations require urgent cardiovascular disease (CVD) prevention. Chronic inflammation, insulin resistance, and visceral adiposity are three core interactive CVD pathogenic pathways, while current biomarkers fail to integrate all three. This study aimed to explore the association of the novel three-dimensional composite index CTI-CVAI with incident CVD and its predictive value in Chinese adults with CKM stages 0-3. This nationwide prospective cohort study used data from the China Health and Retirement Longitudinal Study (CHARLS, 2011-2020), including 6728 participants aged ≥ 45 years with CKM stages 0-3. CTI-CVAI was calculated by combining the C-reactive protein-triglyceride-glucose index (CTI) and Chinese visceral adiposity index (CVAI). Cox regression, restricted cubic spline, survival analysis, ROC curves, and reclassification analysis were used to evaluate its value. Subgroup and multiple sensitivity analyses, including competing-risks models, were conducted to assess the robustness of the results. During a median follow-up of 9 years, the overall CVD incidence was 23.83%. CTI-CVAI elevation showed a linear, dose-dependent correlation with increased CVD risk (P < 0.001). After full confounder adjustment, per 1-SD CTI-CVAI increment increased CVD risk by 32% (HR = 1.32, 95% CI 1.26-1.39, P < 0.001), and the highest quartile exhibited 2.07-fold higher risk than the lowest (HR = 2.07, 95% CI 1.77-2.42, P < 0.001). Restricted cubic spline analysis revealed a linear association between CTI-CVAI and incident CVD (P for non-linearity > 0.05). CTI-CVAI demonstrated improved risk reclassification (NRI = 0.0566, P < 0.001) compared with single biomarkers. The association was stable across most subgroups. All sensitivity analyses yielded reliable, robust results. CTI-CVAI is independently and linearly associated with incident CVD risk in Chinese adults with CKM stage 0-3. As a low-cost, accessible biomarker integrating three key pathological pathways, it optimizes early CVD risk stratification and reclassification, providing a promising tool for targeted CVD prevention in CKM high-risk populations.
- 25 May 2026
- Published by Wiley in International Journal of Cancer
- Vol. 159 (8) , 1937-1948
Cost‐Effectiveness of Initiating Colorectal Cancer Screening at Age 40 Among Average‐Risk Individuals in China
China recently updated its colorectal cancer (CRC) screening guidelines, lowering the recommended initiation age from 45 to 40 years for the general population in response to the rising burden and earlier onset. This study evaluates the cost‐effectiveness of earlier initiation and identifies the optimal screening strategy. A Markov model was developed to compare 48 screening strategies, combining different starting ages, methods (fecal immunochemical test [FIT], multitarget stool DNA [MT‐sDNA] test, methylated Septin 9 [ mSEPT9 ] test, computed tomography colonography [CTC], or colonoscopy), and frequencies, from the healthcare system perspective. Incremental cost‐effectiveness ratios (ICERs) were calculated based on quality‐adjusted life‐years (QALYs), with willingness‐to‐pay thresholds set at one‐ and three‐time China's per‐capita gross domestic product (GDP). The results show that all screening strategies are cost‐effective compared with non‐screening under the three‐time GDP threshold, with nearly half found to be cost‐saving. Starting annual FIT screening at age 40 is the most cost‐effective under both thresholds, with an ICER of US$5381/QALY and reductions of 5.5% in CRC cases and 7.4% in CRC‐related deaths compared with the second‐best strategy of starting at age 45. Starting 10‐yearly colonoscopy screening at age 40 may be optimal, but only under very low thresholds. Both MT‐sDNA and mSEPT9 tests would become the optimal options only if their costs were substantially reduced. The findings are highly robust across sensitivity analyses. This study supports the updated recommendation to lower the CRC screening initiation age for average‐risk individuals and identifies annual FIT screening as the optimal strategy in the current context of China.
- 25 May 2026
- Published by Wiley in International Journal of Cancer
- Vol. 159 (8) , 1937-1948
Cost‐Effectiveness of Initiating Colorectal Cancer Screening at Age 40 Among Average‐Risk Individuals in China
China recently updated its colorectal cancer (CRC) screening guidelines, lowering the recommended initiation age from 45 to 40 years for the general population in response to the rising burden and earlier onset. This study evaluates the cost‐effectiveness of earlier initiation and identifies the optimal screening strategy. A Markov model was developed to compare 48 screening strategies, combining different starting ages, methods (fecal immunochemical test [FIT], multitarget stool DNA [MT‐sDNA] test, methylated Septin 9 [ mSEPT9 ] test, computed tomography colonography [CTC], or colonoscopy), and frequencies, from the healthcare system perspective. Incremental cost‐effectiveness ratios (ICERs) were calculated based on quality‐adjusted life‐years (QALYs), with willingness‐to‐pay thresholds set at one‐ and three‐time China's per‐capita gross domestic product (GDP). The results show that all screening strategies are cost‐effective compared with non‐screening under the three‐time GDP threshold, with nearly half found to be cost‐saving. Starting annual FIT screening at age 40 is the most cost‐effective under both thresholds, with an ICER of US$5381/QALY and reductions of 5.5% in CRC cases and 7.4% in CRC‐related deaths compared with the second‐best strategy of starting at age 45. Starting 10‐yearly colonoscopy screening at age 40 may be optimal, but only under very low thresholds. Both MT‐sDNA and mSEPT9 tests would become the optimal options only if their costs were substantially reduced. The findings are highly robust across sensitivity analyses. This study supports the updated recommendation to lower the CRC screening initiation age for average‐risk individuals and identifies annual FIT screening as the optimal strategy in the current context of China.
- Open Access
- 23 March 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1828826
Correction: Analysis of influenza A, influenza B and Mycoplasma pneumoniae infection in children hospitalized with acute respiratory tract infection in Xi'an from 2021 to 2023
- 23 March 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1828826
Open AccessCorrection: Analysis of influenza A, influenza B and Mycoplasma pneumoniae infection in children hospitalized with acute respiratory tract infection in Xi'an from 2021 to 2023
- Open Access
- 23 March 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
The impact of modifiable social determinants on tuberculosis incidence: insights from a Bayesian spatiotemporal and counterfactual analysis
Addressing social determinants is critical to achieving the End TB Strategy targets. However, the impact of tuberculosis (TB) programmatic indicators amenable to short-term interventions on TB incidence remains underexplored. We aimed to identify modifiable social determinants and evaluate their impact on TB incidence in different risk-specific areas. We compiled individual-level surveillance data on reported pulmonary TB (PTB) cases and county-level data on 12 social determinants between 2011 and 2018 across 108 counties in Shaanxi Province, China. A Bayesian spatiotemporal model quantified associations between PTB incidence rate and social determinants. Model-estimated relative risks (RRs; x-axis) and their annual percentage change (APC; y-axis) were integrated to construct an RR–APC plane diagram for classifying different risk-specific counties. Counterfactual analysis estimated potential reduction in PTB incidence rate if the referral and tracing percentage for PTB patients and suspected cases or the percentage of PTB cases confirmed bacteriologically in these counties were increased to 2018 provincial benchmarks. Five social determinants were significantly associated with PTB incidence rate. A 1% increase in the referral and tracing percentage for PTB patients and suspected cases, per capita housing area, and the percentage of PTB cases confirmed bacteriologically corresponded to reductions in PTB incidence rate of 0.39%, 0.39%, and 0.04%, respectively. In contrast, a 1% increase in the percentage of population aged ≥ 50 years and in the percentage of illiterate population was associated with increases of 0.35% and 0.07%, respectively. The RR–APC plane diagram identified three types of risk areas: four counties in Ankang Municipality with rapidly escalating risks, three counties in Yulin Municipalities with persistently high risks, and three newly emerging high-risk counties in Ankang and Shangluo Municipalities. Counterfactual analysis suggested that increasing the referral and tracing percentage to 94% could reduce PTB incidence rate by 9.24/100,000 to 38.54/100,000 (relative reductions of 8.49% to 28.06%) across different risk-specific counties, and simultaneous improvement in both indicators could achieve reductions of 10.48/100,000 to 38.99/100,000 (9.62% to 28.38%). The referral and tracing percentage for PTB patients and suspected cases and the percentage of PTB cases confirmed bacteriologically are modifiable social determinants on TB incidence rate. Strengthening the effectiveness of referral and tracing mechanisms and expanding bacteriological diagnostic capacity across risk areas may substantially reduce TB burden and accelerate progress towards End TB Strategy targets. The online version contains supplementary material available at 10.1186/s12889-025-26138-x.
- 23 March 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Open AccessThe impact of modifiable social determinants on tuberculosis incidence: insights from a Bayesian spatiotemporal and counterfactual analysis
Addressing social determinants is critical to achieving the End TB Strategy targets. However, the impact of tuberculosis (TB) programmatic indicators amenable to short-term interventions on TB incidence remains underexplored. We aimed to identify modifiable social determinants and evaluate their impact on TB incidence in different risk-specific areas. We compiled individual-level surveillance data on reported pulmonary TB (PTB) cases and county-level data on 12 social determinants between 2011 and 2018 across 108 counties in Shaanxi Province, China. A Bayesian spatiotemporal model quantified associations between PTB incidence rate and social determinants. Model-estimated relative risks (RRs; x-axis) and their annual percentage change (APC; y-axis) were integrated to construct an RR–APC plane diagram for classifying different risk-specific counties. Counterfactual analysis estimated potential reduction in PTB incidence rate if the referral and tracing percentage for PTB patients and suspected cases or the percentage of PTB cases confirmed bacteriologically in these counties were increased to 2018 provincial benchmarks. Five social determinants were significantly associated with PTB incidence rate. A 1% increase in the referral and tracing percentage for PTB patients and suspected cases, per capita housing area, and the percentage of PTB cases confirmed bacteriologically corresponded to reductions in PTB incidence rate of 0.39%, 0.39%, and 0.04%, respectively. In contrast, a 1% increase in the percentage of population aged ≥ 50 years and in the percentage of illiterate population was associated with increases of 0.35% and 0.07%, respectively. The RR–APC plane diagram identified three types of risk areas: four counties in Ankang Municipality with rapidly escalating risks, three counties in Yulin Municipalities with persistently high risks, and three newly emerging high-risk counties in Ankang and Shangluo Municipalities. Counterfactual analysis suggested that increasing the referral and tracing percentage to 94% could reduce PTB incidence rate by 9.24/100,000 to 38.54/100,000 (relative reductions of 8.49% to 28.06%) across different risk-specific counties, and simultaneous improvement in both indicators could achieve reductions of 10.48/100,000 to 38.99/100,000 (9.62% to 28.38%). The referral and tracing percentage for PTB patients and suspected cases and the percentage of PTB cases confirmed bacteriologically are modifiable social determinants on TB incidence rate. Strengthening the effectiveness of referral and tracing mechanisms and expanding bacteriological diagnostic capacity across risk areas may substantially reduce TB burden and accelerate progress towards End TB Strategy targets. The online version contains supplementary material available at 10.1186/s12889-025-26138-x.
- Open Access
- 20 March 2026
- Published by Elsevier in SSRN Electronic Journal
Population Impact and Cost-Effectiveness of Risk-Stratified Cervical Cancer Screening by HPV Vaccination Status in China: A Modelling Study
Background: Globally, expanding human papillomavirus (HPV) vaccination is reshaping cervical cancer risk and challenging uniform screening policies, yet most programmes remain unstratified by vaccination status, risking overscreening and inefficient resource use. We aimed to evaluate population impact and cost-effectiveness of vaccination-status-informed, risk-stratified cervical cancer screening strategies, using China as a case study.Methods: From a health-care system perspective, we developed an extensively calibrated and validated Markov model to evaluate 182 screening strategies across five HPV vaccination status-defined sub-populations. For each sub-population, the optimal strategy was the cost-effectiveness frontier option with an incremental cost-effectiveness ratio (ICER) ≤0.51×China’s 2024 per-capita GDP. We performed multiple sensitivity analyses to test uncertainty.Results: For women without verifiably effective vaccination, the optimal strategy was HPV DNA testing with HPV-16/18 genotyping and artificial intelligence-assisted liquid-based cytology triage every 5 years at ages 25–64 (8 lifetime screens, ICER=US$4,895/quality-adjusted life-year [QALY] gained versus the next least costly non-dominated option). This strategy dominated the status quo, reducing cervical cancer incidence (−10.7%) and mortality (−10.0%) with minimal changes in total resource investment (−0.03%), early diagnosis (0.3%), and overdiagnosis (2.0%). Among vaccinated cohorts, the optimal strategy was HPV DNA testing without triage, requiring 2–4 lifetime screens depending on age at vaccination and vaccine valency, with ICERs of US$1,459–US$6,782/QALY gained versus the next least costly non-dominated option. For vaccinated sub-populations, the optimal strategy dominated the status quo and substantially reduced total resource investment (−72.24%–−36.54%). De-intensified screening led to modest increases in incidence (1.5–36.7%) and mortality (2.3–38.5%), but higher gains in QALYs in three of four vaccinated sub-populations. Early diagnosis declined (−2.1%–−0.5%) but was offset by larger reductions in overdiagnosis (−30.1%–−7.6%). Sensitivity analyses confirmed findings.Conclusion: Vaccination-status-informed, risk-stratified cervical cancer screening in China can improve efficiency while preserving acceptable health outcomes. These findings support risk-stratified screening that aligns screening strategies with underlying carcinogenesis risk.
- 20 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPopulation Impact and Cost-Effectiveness of Risk-Stratified Cervical Cancer Screening by HPV Vaccination Status in China: A Modelling Study
Background: Globally, expanding human papillomavirus (HPV) vaccination is reshaping cervical cancer risk and challenging uniform screening policies, yet most programmes remain unstratified by vaccination status, risking overscreening and inefficient resource use. We aimed to evaluate population impact and cost-effectiveness of vaccination-status-informed, risk-stratified cervical cancer screening strategies, using China as a case study.Methods: From a health-care system perspective, we developed an extensively calibrated and validated Markov model to evaluate 182 screening strategies across five HPV vaccination status-defined sub-populations. For each sub-population, the optimal strategy was the cost-effectiveness frontier option with an incremental cost-effectiveness ratio (ICER) ≤0.51×China’s 2024 per-capita GDP. We performed multiple sensitivity analyses to test uncertainty.Results: For women without verifiably effective vaccination, the optimal strategy was HPV DNA testing with HPV-16/18 genotyping and artificial intelligence-assisted liquid-based cytology triage every 5 years at ages 25–64 (8 lifetime screens, ICER=US$4,895/quality-adjusted life-year [QALY] gained versus the next least costly non-dominated option). This strategy dominated the status quo, reducing cervical cancer incidence (−10.7%) and mortality (−10.0%) with minimal changes in total resource investment (−0.03%), early diagnosis (0.3%), and overdiagnosis (2.0%). Among vaccinated cohorts, the optimal strategy was HPV DNA testing without triage, requiring 2–4 lifetime screens depending on age at vaccination and vaccine valency, with ICERs of US$1,459–US$6,782/QALY gained versus the next least costly non-dominated option. For vaccinated sub-populations, the optimal strategy dominated the status quo and substantially reduced total resource investment (−72.24%–−36.54%). De-intensified screening led to modest increases in incidence (1.5–36.7%) and mortality (2.3–38.5%), but higher gains in QALYs in three of four vaccinated sub-populations. Early diagnosis declined (−2.1%–−0.5%) but was offset by larger reductions in overdiagnosis (−30.1%–−7.6%). Sensitivity analyses confirmed findings.Conclusion: Vaccination-status-informed, risk-stratified cervical cancer screening in China can improve efficiency while preserving acceptable health outcomes. These findings support risk-stratified screening that aligns screening strategies with underlying carcinogenesis risk.
- Open Access
- 6 March 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1762939
Analysis of influenza A, influenza B and Mycoplasma pneumoniae infection in children hospitalized with acute respiratory tract infection in Xi’an from 2021 to 2023
Objective: To evaluate the occurrence of three pathogens, influenza virus A (FluA), influenza virus B (FluB) and Mycoplasma pneumoniae (Mp) in children hospitalized with acute respiratory tract infection (ARTI) between 2021 and 2023. Methods: FluA, FluB and Mp were detected by antigen/antibody kit in specimens from 29,014 children with ARTI admitted to Xi’an Children’s Hospital. Results: The total pathogen detection rate was 43.79% (12,707/29014) with 30.14% (8,745/29014) Mp-positive cases, 7.08% (55/29014) FluA-positive and 6.57% (1907/29014) FluB-positive. Total detection rates were 28.05% (2,472/8813) in 2021, 29.38% (2,550/8680) in 2022 and 66.70% (7,685/11521) in 2023. Co-infection rates with two or more pathogens increased over the period of interest from 0.75% (66/8813) in 2021, 0.93% (81/8680) in 2022 to 2.38% (274/11521) in 2023 ( χ 2 = 115.931, p < 0.001). FluA detection also increased and was present in 0.53% cases in 2021, 6.01% in 2022 and 12.90% in 2023, reaching a peak in February 2023 of 17.83% and March 2023 of 64.42%. FluB detection rates were more stable at 5.25% in 2021, 7.67% in 2022 and 6.75% in 2023, reaching a peak of 22.17% in December 2023. Mp detection was higher in 2023 at 47.05% with a peak of 82.21% in October 2023 than in 2021 (15.89%) or 2022 (15.69%). More FluA-positive cases were seen in the >12 age groups than in younger children and FluB detection also increased with age. Mp infection was detected in the >4 age group. Conclusion: The pathogen spectrum and epidemiology of ARTI changed between 2021 and 2023. Age-specific bandings of infection were seen in the cohort of children. Outbreaks of FluA, FluB and Mp influence the pathology of ARTI.
- 6 March 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1762939
Open AccessAnalysis of influenza A, influenza B and Mycoplasma pneumoniae infection in children hospitalized with acute respiratory tract infection in Xi’an from 2021 to 2023
Objective: To evaluate the occurrence of three pathogens, influenza virus A (FluA), influenza virus B (FluB) and Mycoplasma pneumoniae (Mp) in children hospitalized with acute respiratory tract infection (ARTI) between 2021 and 2023. Methods: FluA, FluB and Mp were detected by antigen/antibody kit in specimens from 29,014 children with ARTI admitted to Xi’an Children’s Hospital. Results: The total pathogen detection rate was 43.79% (12,707/29014) with 30.14% (8,745/29014) Mp-positive cases, 7.08% (55/29014) FluA-positive and 6.57% (1907/29014) FluB-positive. Total detection rates were 28.05% (2,472/8813) in 2021, 29.38% (2,550/8680) in 2022 and 66.70% (7,685/11521) in 2023. Co-infection rates with two or more pathogens increased over the period of interest from 0.75% (66/8813) in 2021, 0.93% (81/8680) in 2022 to 2.38% (274/11521) in 2023 ( χ 2 = 115.931, p < 0.001). FluA detection also increased and was present in 0.53% cases in 2021, 6.01% in 2022 and 12.90% in 2023, reaching a peak in February 2023 of 17.83% and March 2023 of 64.42%. FluB detection rates were more stable at 5.25% in 2021, 7.67% in 2022 and 6.75% in 2023, reaching a peak of 22.17% in December 2023. Mp detection was higher in 2023 at 47.05% with a peak of 82.21% in October 2023 than in 2021 (15.89%) or 2022 (15.69%). More FluA-positive cases were seen in the >12 age groups than in younger children and FluB detection also increased with age. Mp infection was detected in the >4 age group. Conclusion: The pathogen spectrum and epidemiology of ARTI changed between 2021 and 2023. Age-specific bandings of infection were seen in the cohort of children. Outbreaks of FluA, FluB and Mp influence the pathology of ARTI.